Successful PDGFR-α/β targeting with imatinib in uterine sarcoma

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1898-1899

  Trojan, A ^a   Montemurro, M ^b   Kamel, M ^c   Kristiansen, G ^d  

^a KLINIK IM PARK   (Switzerland)

^b Centre Pluridisciplinaire d'Oncologie   (Switzerland)

^c Department of Radiology ^*  (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ABNORMAL FECES; AGED; ARTICLE; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; DRUG TARGETING; ENDOMETRIUM BIOPSY; ENDOMETRIUM SARCOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MICROCYTIC ANEMIA; OVARIECTOMY; OVARY METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL HYSTERECTOMY;

AGED; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SARCOMA; UTERINE NEOPLASMS;

EID: 71049146045     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp431     Document Type: Article

References (9)

1. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004; 93: 204-208.
2. Giuntoli RL II, Metzinger DS, DiMarco CS et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003; 89: 460-469.
3. Tuveson DA, Fletcher JA. Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol 2001; 13: 249-255.
4. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
5. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
6. Adams SF, Hickson JA, Hutto JY et al. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol 2007; 104: 524-528.
7. Zafrakas M, Theodoridis TD, Zepiridis L et al. KIT protein expression in uterine sarcomas: An immunohistochemical study and review of the literature. Eur J Gynaecol Oncol 2008; 29: 264-266.
8. Chirieac LR, Trent JC, Steinert DM et al. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer 2006; 107: 2237-2244.
9. Duensing A, Joseph NE, Medeiros F et al. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 2004; 64: 5127-5131.